Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rat experimental autoimmune neuritis

Journal of Neuroimmunology

Volumn 85, Issue 2, 1998, Pages 137-145

  Zou, Li Ping ^a   Zhu, Jie ^a   Deng, Guo Min ^a   Levi, Michael ^b   Wahren, Britta ^b   Diab, Asim ^a   Hillert, Jan ^a   Link, Hans ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Autoimmunity; ELISPOT; Experimental autoimmune neuritis (EAN; Guillain Barre syndrome; Mocosal tolerance; P2 peptide

Indexed keywords

GAMMA INTERFERON; PEPTIDE; PEPTIDE P2 [57-81]; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; GUILLAIN BARRE SYNDROME; HELPER CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; INTRANASAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; NEURITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; RELAPSE; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; AMINO ACID SEQUENCE; ANIMALS; CYTOKINES; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; MYELIN P2 PROTEIN; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; PEPTIDE FRAGMENTS; RATS; RATS, INBRED LEW; RNA, MESSENGER;

EID: 0032524519     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00022-8     Document Type: Article

References (32)

1. Adelmann M., Linington C. Molecular mimicry and the autoimmune response to the peripheral nerve myelin P0 glycoprotein. Neurochem. Res. 17:1992;887-891.
2. Brideau R.J., Carter P.B., McMaster W.R., Mason D.W., Williams A.F. Two subsets of rat T lymphocytes defined with monoclonal antibodies. Eur. J. Immunol. 10:1980;609-615.
3. Critchfield J.M., Lenardo M.J. Antigen-induced programmed T cell death as a new approach to immune therapy. Clin. Immunol. Immunopathol. 75:1995;13-19.
4. Dawson W.B., Phillips L.H. A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis. Clin. Neuropharmacol. 18:1995;377-390.
5. Derynck R., Jarrett J.A., Chen E.Y., Eaton D.H., Bell J.R., Assoian R.K., Roberts A.B., Sporn M.B., Goeddel D.V. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 316:1985;701-705.
6. Dick A.D., Cheng Y.F., McKinnon A., Liversidge J., Forrester J.V. Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. Brit. J. Opthalmol. 77:1993;171-175.
7. Dijkema R., van der Meide P.H., Dubbeld M., Caspers M., Wubben J., Schellekens H. Cloning expression and purification of rat IFN-γ Meth. Enzymol. 119:1986;453-464.
8. Gaur A., Wiers B., Liu A., Rothbard J., Fathman C.G. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science. 258:1992;1491-1494.
9. Hoyne G., Bourne T., Kristensen N., Hetzel C., Lamb J. From epitopes to peptides to immunotherapy. Clin. Immunol. Immunopathol. 80:1996;23-30.
10. Kadlubowski M., Hughes R.A. Identification of the neuritogen for experimental allergic neuritis. Nature. 277:1979;140-141.
11. Khoury S.J., Hancock W.W., Weiner H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differentiated upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1992;1355-1364.
12. Javed N.H., Gienapp I., Cox K., Whitacre C.C. Oral tolerance in experimental autoimmune encephalomyelitis: specificity of peptide-induced oral tolerance. Ann. N.Y. Acad. Sci. 778:1996;393-394.
13. Linington C., Izumo S., Suzuki M., Uyemura K., Meyermann R., Wekerle H. A permanent rat T cell line that mediates experimental allergic neuritis in the Lewis rats in vivo. J. Immunol. 133:1984;1946-1950.
14. Linington C., Lassmann H., Ozawa K., Kosin S., Mongan L. Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: induction of experimental allergic neuritis (EAN) by P0 protein-specific T cell lines. Eur. J. Immunol. 22:1992;1813-1817.
15. Ma C.G., Zhang G.X., Xiao B.G., Wang Z.Y., Link J., Olsson T., Link H. Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-γ-expressing Th1-like cells and up-regulation of TGF-β mRNA in mononuclear cells. Ann. N.Y. Acad. Sci. 778:1996;273-287.
16. McKnight A.J., Barclay A.N., Mason D.W. Molecular cloning of rat interleukin 4 cDNA and analysis of the cytokine repertoire of subsets of CD4+ T cells. Eur. J. Immunol. 21:1991;1187-1194.
17. McMaster W.R., Williams A.F. Identification of Ia glycoproteins in rat thymus and purification from rat spleen. Eur. J. Immunol. 9:1979;426-433.
18. Metzler B., Wraith D.C. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int. Immunol. 5:1993;1159-1165.
19. Moore K.W., Vieira P., Fiorentino D.F., Trounstine M.L., Khan T.A., Mosmann T.R. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science. 248:1990;1230-1234.
20. Norton W.T., Poduslo S.E. Myelination in rat brain. Method of myelin isolation. J. Neurochem. 21:1973;749-757.
21. Olee T., Powers J.M., Brostoff S.W. A T cell epitope for experiment allergic neuritis. J. Neuroimmunol. 19:1988;167-173.
22. Olee T., Powell H.C., Brostoff S.W. New minimum length requirement for a T cell epitope for experimental allergic neuritis. J. Neuroimmunol. 27:1990;187-190.
23. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell. 76:1994;241-251.
24. Plasma Echage/Sandoglobulin Guillain-Barré syndrome Trial Group Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatment in Guillain-Barré syndrome. Lancet. 349:1997;225-230.
25. Shin H.C., McFarlane E.F., Pollard J.D., Watson E.G. Induction of experimental allergic neuritis with synthetic peptides from myelin P2 protein. Neurosci. Lett. 102:1989;309-312.
26. Shirai T., Shimizu N., Horiguchi S., Ito H. Rat TNF alpha. Agric. Biol. Chem. 53:1989;1733-1736.
27. Staines N.A., Harper N., Ward F.J., Thompson H.S., Bansal S. Arthritis: animal models of oral tolerance. Ann. N.Y. Acad. Sci. 778:1996;297-305.
28. Waksman N.H., Adams R.D. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvant. J. Exp. Med. 102:1955;213-225.
29. Williams A.F., Galfre G., Milstein C. Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: differentiation antigens of rat lymphocytes. Cell. 12:1977;663-673.
30. Ye J., Young H.A. Negative regulation of cytokine gene transcription. FASEB J. 11:1997;825-833.
31. Zhu J., Mix E., Olsson T., Link H. Cellular mRNA expression of interferen-γ, interleukin 4 and transforming growth factor-β by rat mononuclear cells stimulated with peripheral nerve antigens in experimental allergic neuritis. Clin. Exp. Immunol. 98:1994;306-312.
32. Zhu J., Deng G.M., Levi M., Wahren B., Diab A., van der Meide P.H., Link H. Prevention of experimental autoimmune neuritis by nasal administration of P2 protein peptide 57-81. J. Neuropathol. Exp. Neurol. 57:1998;291-301.